Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Holly Hartman-Adams, Robert Gerbo, Saira George
…ration of three and four months, respectively. Treatment of drug-susceptible TB disease includes an eight-week intensive phase with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol), followed by a continuation phase lasting 18 weeks or more, with two drugs based on s…
Hartman-Adams H, Gerbo RM, George S
…ration of three and four months, respectively. Treatment of drug-susceptible TB disease includes an eight-week intensive phase with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol), followed by a continuation phase lasting 18 weeks or more, with two drugs based on s…
Shaji B, Arun Thomas ET, Sasidharan PK
…rculosis years before the advent of potent anti-tuberculous drugs, as a result of the improved standards of living and good nutrition. But even with the availability of powerful anti-tuberculous drugs, India still has a long road ahead to reach the "End TB by 2025" goal. One of t…
Dick Menzies
The objective of the study is to compare outcomes from three different strategies for the management of household (HH) contacts of individuals with newly diagnosed microbiologically confirmed active pulmonary TB. The study is a cluster randomized trial with three arms of equal si…
Harries AD, Kumar AMV, Satyanarayana S, Takarinda KC, Timire C, et al.
…d and rifapentine-isoniazid) and treatments for contacts of drug-resistant patients; iv) issues with programmatic scale-up of treatment including policy considerations, ruling out active TB, time to start treatment, safety, uninterrupted drug supplies and treatment adherence; and…
Emanuela da Rocha Carvalho, Emil Kupek
…rty, those experiencing homelessness, those who use illicit drugs, and those with diabetes mellitus. Missing data were frequent among individuals living with HIV; people of African, Indigenous, or Asian descent; and those exposed to drug-resistant TB. More than 10% of LTBI cases …
Kendra Brett, Melissa Severn
…of antibiotic treatments, which often include more than one drug., Incomplete treatment adherence is a major challenge of TB treatment, and failing to complete the treatment can result in persistent disease or the development of drug-resistant TB. One of the strategies for improv…
Brett K, Severn M
…of antibiotic treatments, which often include more than one drug., Incomplete treatment adherence is a major challenge of TB treatment, and failing to complete the treatment can result in persistent disease or the development of drug-resistant TB. One of the strategies for improv…
Gálvez L, Fica A, Hidalgo P, Kyonen M, Hiplán E, et al.
…treatment failure without the emergence of antituberculosis drug resistance. The association of gastroparesis with isoniazid was considered definitive when applying at least two causality protocols. Gastroparesis associated with isoniazid should be added to the list of adverse ef…
D. Fernando Estrada, Christopher S. Campomizzi, Shaun Ferguson, Emelie‐Jo Scheffler, Natalie Jay, et al.
… in the development of tuberculosis (TB). The rise of multi‐drug resistant forms of TB, combined with the fact that one third of the world’s population are carriers of latent TB, underscores the need for the development of novel anti‐TB agents. A current drug target is the cytoch…
S Vijayalakshmi, J.S. Akshata, Anushree Chakraborthy, Swathi Karanth, Swapna Ramaswamy, et al.
…eived systemic cor-ticosteroids and other immunosuppressive drugs like tocilizumab during the COVID-19 illness treatment. More than 50% of the patients had negative smears for acid-fast bacilli and were diag-nosed using rapid molecular methods like CBNAAT and LPA. Drug-resistant …
…tment for RD patients suspected of ATB, (6) how to diagnose drug-resistant TB in RD patients with ATB, (7) the characteristics and management of subclinical TB in RD patients with ATB, (8) the recommended treatment regimens and courses for TB in RD patients, (9) the interaction b…
Mandeep Chouhan, Mukesh Kumar, Richa Mishra, Saurabh Gupta, Prashant Kumar Tiwari, et al.
… society that is worsening day by day with the emergence of drug-resistant TB as well as risks associated with latent TB. Isocitrate lyase (ICL) has been shown as a potential target that plays a role in the latent/ dormant stage of. Several inhibitors against ICL have been design…
Nunes JES, Duque MA, de Freitas TF, Galina L, Timmers LFSM, et al.
…the inefficacy of prophylactic measures and the increase of drug-resistant M. tuberculosis strains, there is a clear and urgent need for the development of new and more efficient chemotherapeutic agents, with selective toxicity, to be implemented on patient treatment. The compone…
Urban M, Šlachtová V, Brulíková L
…is (TB) infection, the HIV pandemic, and increasing anti-TB drug resistance. Therefore, unexplored chemical scaffolds directed towards new molecular targets are increasingly desired. In this context, mycobacterial energy metabolism, particularly the oxidative phosphorylation (OP)…
Н. П. Бабушкина, E. Yu. Bragina
…tuberculosis development is due to the increase in cases of drug resistance, coinfection with HIV and hepatitis, and the lack of an effective vaccine. However, the pathogenesis of tuberculosis remains insufficiently studied at present. A significant role is assigned to hereditary…
Mori G, Orena BS, Chiarelli LR, Degiacomi G, Riabova O, et al.
…ction, Mycobacterium tuberculosis can persist unaffected by drugs for years in a non-replicating state with low metabolic activity. The rate of the successful tuberculosis treatment is curbed by the presence of these non-replicating bacilli that can resuscitate after decades and …
I. M. Poiasnyk
…e diseases, which is due to the high effectiveness of these drugs in reducing disease activity. Immunological defects in systemic connective tissue diseases, a high total dose of corticosteroids in therapy cause the activation of latent tuberculosis infection and the rapid develo…
Hannah Jarvis, Onn Min Kon
…use of rifampicin, isoniazid, pyrazinamide, and ethambutol. Drug resistance is an increasing problem. Around 1.5 million people die from TB each year. Infection tends to present with a worsening of chronic respiratory symptoms in patients with underlying lung diseases. Diagnosis …
Dick Menzies, MD
… an independent three member review panel, blinded to study drug. In this phase, among 420 subjects randomized to 4RIF overall rate of Grade 3-4 SAE was 2.4% compared to 5.6% among the 427 taking 9INH (p=.02). Grade 3-4 hepatotoxicity was very significantly lower (0.7% vs 3.8%; p…
Vadakkan Devassy T, K V S, Jacob A, Meleppat VM
…nd appropriate investigations so as to minimize the risk of drug resistance with anti-tuberculosis monotherapy used in LTBI treatment. To add on to literature, Non tuberculous mycobacteria are universally present environmental organisms. However, in immunocompromised children esp…
Topluoglu S, Taylan-Ozkan A, Alp E
…pre-assessment of data such as TB prevalence and incidence, drug-resistance status, prevailing major biological and behavioral risk factors for TB, resource requirements, a contingency plan for procurement and supply chain, surveillance, monitoring and evaluation tools, health fa…
Tom Wingfield, Stéphane Verguet
…heir importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru.PLoS Med. 2014; 11: e1001675Crossref PubMed Scopus (146) Google Scholar, 15Wingfield T Tovar MA Huff D et al.The economic effects of supporting tuberculosis-affected hous…
Wilkie MEM
… of LTBI and TB disease, with the addition of antimicrobial drug resistance means there is a desperate need for a safe and effective TB vaccine. BCG is the only licensed vaccine and extremely variable in efficacy. However, BCG potentially exerts a non-specific beneficial effect -…
Andrey S Borisov, MD, MPH, Robert Belknap, MD, Robert Belknap, MD
…the toxicity and tolerability by comparing the rates of any drug-related grade 3 or 4 adverse events or death between the DOT arm and the SAT arms (both combined and individually) * To compare the frequency, timing, and causes for failure to complete treatment between the DOT arm…